These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection. Moyo-Gwete T; Richardson SI; Keeton R; Hermanus T; Spencer H; Manamela NP; Ayres F; Makhado Z; Motlou T; Tincho MB; Benede N; Ngomti A; Baguma R; Chauke MV; Mennen M; Adriaanse M; Skelem S; Goga A; Garrett N; Bekker LG; Gray G; Ntusi NAB; Riou C; Burgers WA; Moore PL PLoS Pathog; 2023 Nov; 19(11):e1011772. PubMed ID: 37943890 [TBL] [Abstract][Full Text] [Related]
5. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. Sadoff J; Le Gars M; Shukarev G; Heerwegh D; Truyers C; de Groot AM; Stoop J; Tete S; Van Damme W; Leroux-Roels I; Berghmans PJ; Kimmel M; Van Damme P; de Hoon J; Smith W; Stephenson KE; De Rosa SC; Cohen KW; McElrath MJ; Cormier E; Scheper G; Barouch DH; Hendriks J; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H N Engl J Med; 2021 May; 384(19):1824-1835. PubMed ID: 33440088 [TBL] [Abstract][Full Text] [Related]